GFAP and Alzheimer disease: In addition, novel markers such as glial fibrillary acidic protein (GFAP) in the blood or CNS have been proposed for the clinical management of AD, and single-cell RNA maps of astrocyte-related genes have been introduced in AD animal models (Carter et al., 2019; Endo et al., 2022).